Background: Concurrent chemoreirradiation therapy (CRRT) offers a therapeutic option for patients with locoregionally recurrent squamous cell carcinoma of the head and neck (SCCHN). We hypothesized that response to induction chemotherapy (IC) would improve outcome and predict increased survival.
introduction Worldwide, there are 640 000 cases of head and neck cancer annually, with 45 660 cases in the United States [1] . Squamous cell carcinoma of the head and neck (SCCHN) presents as a locoregional disease as a minority of patients present with distant metastasis and the majority of recurrences are in the primary tumor bed or regional lymph nodes [2, 3] . Treatment options for locoregional recurrence or second primary tumors remain limited. Low-volume resectable disease is best approached by surgical intervention. However, most patients with locoregional recurrence have large tumor volumes or comorbidities, which render them unresectable or ineligible for resection [4] , and salvage surgery alone yields long-term survival in 10%-15% of patients. While chemotherapy is offered for palliative purposes, it is less effective in patients who have had prior radiation exposure [5, 6] . Therefore, reirradiation usually with concurrent chemotherapy has been pursued to improve long-term survival in previously radiated patients with locoregional SCCHN recurrence or second primary cancers.
Nonrandomized trials evaluating reirradiation or concurrent chemoreirradiation therapy (CRRT) in a multimodality treatment regimen suggest long-term survival in 10%-40% of patients [7, 8] . Concomitant chemotherapy and reirradiation in specific patients represents a viable treatment option. In a retrospective review of trials using reirradiation and chemotherapy at the University of Chicago, the ability to undergo surgical salvage whenever possible was a predictor of long-term outcome [9] . Moreover, in a randomized study assessing the efficacy of adjuvant CRRT after salvage surgery, subjects receiving CRRT had significantly improved disease-free survival [10] . These studies suggest that a combined approach of surgery and CRRT may offer the optimal strategy for the limited patient population with resectable tumors and in adequate health to undergo an operation.
We, therefore, undertook this prospective study in previously irradiated, recurrent or second primary SCCHN patients to evaluate a sequential regimen of induction chemotherapy (IC), resection if possible (determined at study entry), and CRRT. We added IC hypothesizing that response would be associated with improved survival and could offer a dynamic prognostic metric to select patients most appropriate for aggressive therapy [11] . Furthermore, by assessing resectability before starting therapy, this study could evaluate the role of surgery in locoregionally recurrent SCCHN. Pemetrexed and gemcitabine were chosen as IC as patients with recurrent disease typically have not been exposed to these agents. In patients with recurrent and metastatic head and neck cancer, pemetrexed has a response rate (RR) of 26%, with a response duration of 5.6 mosnths [12] , and gemcitabine has an RR of 13%-30% [13, 14] . These RRs are similar to those obtained using other commonly used chemotherapeutic agents for this indication [15] . This was therefore an exploratory analysis evaluating two non-cross-reactive chemotherapeutic agents in recurrent head and neck cancer.
patients and methods
patients Eligible patients were ‡18 years with histologically proven, recurrent or second primary, previously irradiated SCCHN, without clinically measurable metastatic disease or low-volume metastatic disease where local palliation was warranted [16, 17] . Prior radiotherapy had to be completed at least 4 months before and chemotherapy at least 1 month before initiating treatment, and patients had to have recovered from any adverse effects. Eastern Cooperative Oncology Group performance status of one or less and normal organ function were required. Institutional review board approval and informed consent were obtained. Patients were excluded if they had white blood cell count <3000/ll, absolute neutrophil count of <1500/ll, platelet count of <100 000/ll, creatinine clearance <45 ml/min, total bilirubin level >1.5 times the upper limit of normal, or transaminases >2.5 times the upper limit of normal. At screening, all patients underwent evaluation by surgical, radiation, and medical oncologists. Triple endoscopy under anesthesia was carried out if feasible and appropriate. Resectability was determined by clinical exam and computed tomography (CT) or magnetic resonance imaging (MRI) scans. Metastatic work-up was completed with CT or MRI scans of the head, neck, and chest. A positron emission tomography was carried out if indicated. Dental and speech-swallow evaluation were obtained. All prior radiotherapy courses were evaluated by the attending physician to assess tolerability of chemoreirradiation. Patients were considered not surgical candidates if they had evidence of distant metastatic disease, inability to adequately resect gross disease, or medical comorbidities that precluded resection. ) and carboplatin [area under the curve (AUC) 6 amended to 5 following high rate of neutropenia seen in first five patients]. Toxic effects were assessed using National Cancer Institute-Common Toxicity Criteria version 2.0.
Surgery was carried out after IC but before concurrent chemoradiotherapy. The precise surgical technique employed was left to the discretion of the treating surgeon. All surgeries attempted to resect all gross disease and render wounds safe for chemoreirradiation.
All patients underwent contrast-enhanced CT-based radiation planning with custom-made immobilization before and after induction. These scans were fused for radiation target volume delineation. The attending radiation oncologist outlined all radiographically and clinically evident cancer as the gross tumor volume (GTV) on each slice of the planning CT scan. For postoperative cases, the clinical target volume (CTV) was created based on the presurgical tumor volume and high-risk regions of the surgical bed. The GTV or CTV was expanded 1.5-2 cm in all dimensions to create the planning target volume (PTV). Subsequently, the PTV was trimmed to avoid extension through the skin or into the spinal canal. Elective irradiation of close proximity nodal regions was uncommon and was carried out at the discretion of the treating radiation oncologist. For radiation planning, either three-dimensional conformal or intensity-modulated radiotherapy was used. Radiation planning placed priority on limiting lifetime dose to the spinal cord to 50 Gy. Acceptable reirradiation plans ensured 100% GTV coverage by the prescription dose and 95% PTV coverage by 95% of the prescription dose. Radiation dose to gross disease was 70 and 60-66 Gy to postoperative patients delivered in 1.8-to 2-Gy daily fractions.
All patients were evaluated weekly during treatment and subsequently followed at least every 3 months for 2 years and then every 6 months for subsequent years. Radiographic evaluation was carried out 1 month following chemoradiotherapy and every 6 months for 3 years. Patients were discontinued from study if their disease progressed; they had intercurrent illness that prevented further administration of treatment, unacceptable toxic effects, or withdrawn voluntarily; or there were change in the patient's 
statistical considerations
The primary end point was 1-year overall survival (OS). The planned sample size was 36 patients and the study was designed to have 90% power with one-sided a = 0.10 to reject the null hypothesis that 1-year OS is £20% versus the alternate hypothesis of 1-year survival ‡40%. Based on this design, the treatment would be declared effective if ‡11 or patients survived 1 year.
Secondary end points included progression-free survival (PFS), overall response rate after IC, overall response rate after concurrent chemoradiotherapy, and toxicity. Patient characteristics at baseline and toxicity frequencies were summarized using descriptive statistics. OS was defined as the time from study enrollment until death due to any cause and PFS was defined as the time from enrollment until disease progression or death. Radiological and clinical response was evaluated by RECIST criteria. For the analysis of OS between groups based on induction therapy outcome (response to induction and post-induction surgery), survival time from the date of induction therapy completion was also analyzed. One-year OS and PFS were estimated using the method of Kaplan-Meier, and differences between groups were analyzed using the log-rank test. In addition, local and distant progression rates were analyzed using cumulative incidence functions. Cumulative incidence was estimated using the 'cmprsk' (developed by Robert Gray) package in R (R Development Core Team) and confidence intervals (CI) for cumulative incidence estimates were constructed using the method described in Choudhury [18] . Other analyses were carried out using Stata version 10. (Table 1) . Patients were followed for disease progression and OS through April 2010.
response to IC
Of the 35 patients enrolled (Figure 1 ), 31 were assessable for clinical and radiographic response to induction. Four subjects did not complete IC due to treatment-related death (one) and voluntary withdrawal (three). Among assessable patients, 11 (35%) responded clinically [1 complete response (CR) and 10 partial response (PR)], 9 patients (29%) had stable disease (SD), and 11 patients progressed (35%). Based on radiological assessment of response to induction, 12 patients (39%) had PR, 10 SD (32%), and 9 disease progression (29%). Overall objective clinical RR was 35.5% (95% CI 19.2% to 54.6%), and radiological RR was 38.7% (95% CI 21.8% to 57.8%).
surgical resection
Of the 35 patients entered in the study, 30 were considered surgical candidates at initial assessment. Twenty patients (61%) underwent surgical resection after induction therapy of which 5 had pathologically positive margins. Patients did not undergo resection because of CR (one), refusal (two), development of distant metastatic disease (two), concurrent esophageal cancer (one), locoregional progression (one), and withdrawal from study (three). In total, four patients who were resectable before IC were deemed unresectable afterward. None of the five patients who were unresectable at baseline became surgical candidates following IC.
response to chemoreirradiation
Eleven subjects never started chemoreirradiation. Three subjects withdrew during IC and one patient discontinued due to renal failure and subsequent death. Four additional subjects completed IC but withdrew from protocol because of progressive disease (PD), two as distant failures. Three subjects did have surgical resection but did not have concurrent chemoreirradiation due to fatal myocardial infarct following surgery (one), development of metastatic disease after a complicated postoperative course (one), and inability to adhere to treatment (one).
Twenty-four patients received chemoreirradiation. Of these subjects, 17 had induction followed by surgery and 7 had induction only before chemoreirradiation. Nineteen subjects received >59.5 Gy. Six subjects did not complete chemoradiotherapy: one for fatal hemorrhagic events, one death of unknown cause, one death due to suicide, two withdrawals (one completed different chemoreirradiation regimen and one hospitalization for toxic effects, neutropenia, hematemesis, dehydration, and thrombosis), and one PD.
Following chemoreirradiation, 11 patients were assessable for radiographic response including 4 CR, 2 PR, and 5 PD. Twenty-four patients were unassessable for radiographic response, including 6 with no evidence of disease before chemoreirradiation, or discontinued study before chemoreirradiation (11), death during induction (1), early death during chemoreirradiation (3), and withdrawal from protocol (2).
survival
Fifteen patients had OS >12 months allowing rejection of the null hypothesis. The 1-year OS and PFS were 43% (95% CI 26% to 58%) and 20% (95% CI 9% to 34%), respectively ( Figure 2 ). The 1-year OS in those who responded (CR or PR) to induction was 64% (95% CI 30% to 85%) versus 35% (95% CI 16% to 55%) for those who did not respond to induction. For those who were able to undergo surgical resection, 1-year OS was 45% (95% CI 23% to 65%), and for those who did not, 1-year OS was 40% (95% CI 16% to 63%). The median OS and PFS were 9.5 (95% CI 7.2 15.4) months and 5.5 (95% CI 3.6-8.3) months, respectively. Three patients were alive with no evidence of disease and one patient was alive with disease at the last follow-up. The median follow-up for the four surviving patients was 45.6 months (range 36.1-50.4 months).
OS was compared between patients who responded to IC and those who did not ( Figure 3A) , regardless of surgical intervention. Four patients who were unassessable at the end of induction were excluded. Response to induction therapy was associated with longer survival (P = 0.019). Similarly, OS from the date of completion of induction therapy was also higher among those who responded to induction (P = 0.02). No differences in OS were observed between patients who were able to undergo post-induction surgery versus those who were not (P = 0.73; Figure 3B ). We further compared OS and PFS for several important baseline prognostic factors: prior chemotherapy, smoking and alcohol use history, and age. OS was somewhat higher for the six patients who have never consumed alcohol (P = 0.07; Figure 3C ) but was not significantly different for the other prognostic factors. PFS was higher for those who had not had prior chemotherapy (P = 0.04) including three subjects who are still alive.
PFS was higher for those who had not had prior chemotherapy (P = 0.04) including three subjects who are still alive, possibly reflecting that these patients had a different tumor biology due to lower stage at initial presentation or were healthier. The locoregional progression rate was lower than distant progression rate. Overall, 8 patients progressed locally and 23 distantly. At 12 months, cumulative incidence of local and distant progression was 18% (95% CI 7% to 32%) and 62% (95% CI 43% to 76%), respectively ( Figure 3D ). One patient was unassessable for PD due to early death (suicide). toxicity Treatment-related toxicity during IC was consistent with that given the agents (Table 2) . One death occurred during IC due to renal failure. Pemetrexed and carboplatin were feasibly administered with radiotherapy (Table 2) , although, as mentioned, the dose of carboplatin needed to be reduced to AUC 5 after near-universal neutropenia was observed at AUC 6 in the first five patients. Four deaths occurred during chemoradiotherapy, two due to hemorrhagic events. During the course of treatment and follow-up, nine subjects experienced hemorrhage from the carotid artery or one of its named branches. One patient experienced hemorrhage during original article Annals of Oncology treatment, four within 6 months of completing treatment, and four between 6 and 12 months. Five of the nine patients survived the hemorrhagic event. In addition, one subject developed an orocutaneous fistula.
discussion
Treatment of SCCHN patients with locoregional recurrence or second primary cancers continues to be a challenge, especially for those who are reasonable candidates for curative-intent therapy. We report mature results of a phase II study in previously irradiated patients and demonstrate feasibility of this outpatient regimen with 1-year OS and PFS rates of 43% and 20%, respectively. However, at the time of data cut-off, there are only four survivors representing 11% of the original study cohort. Although the regimen was overall well tolerated and the null hypothesis rejected, long-term disease control remains elusive for the majority of patients. The results of our study are similar to previous trials that have been carried out in this patient population. While there are patients who achieve long-term survival with this approach, more novel approaches are necessary. Perhaps there may be a role for targeted agent with reirradiation such as sunitinib and cetuximab currently under investigation at the University of Chicago. This study, however, departed from prior efforts employing chemoreirradiation and challenges current treatment paradigms. This is the first study to our knowledge that evaluated resectability prospectively in a chemoreirradiation trial. Resectability was documented before commencing therapy allowing prospective review of outcomes from the initial management decisions as opposed to postoperative studies reporting results on patients who survive surgery and maintain fitness. Prior data support that subjects who undergo surgery have better OS compared with those that do not (nine). However, we could not demonstrate a difference in outcome based on whether surgery was carried out. Given the small sample size, this could be due to a variety of factors, including PD or changes in patient wishes during IC, general indicator of advanced disease that is no longer successfully addressed surgically and requires chemoradiotherapy. This might have been avoided if surgery was undertaken first but also underscores the impact of perioperative morbidity and mortality on long-term survival in this patient population. The poor prognosis of this group of patients observed in multiple trials using surgery and/or CRRT demonstrates the need for more active drugs and novel approaches. Parameters to select which patients would benefit from surgery and chemoreirradiation remain elusive. We hypothesized that IC could be used as a strategy to determine which patients would be most appropriate for aggressive treatment. Indeed, among subjects who completed IC, those who responded had an improved OS (P = 0.02). Similar results have been noted using IC in previously untreated patients but in that setting the RR often exceeds 80% offering less discretion 21 [19] [20] [21] . Plausible biological explanation of improved outcome in responders to induction might lie in cross-resistance between chemotherapy and radiotherapy. The extension of this hypothesis would be to only offer curative-intent therapy including chemoreirradiation to patients who respond to IC, while nonresponders would not be subjected to the serious toxicity and morbidity of this approach. This has to be further tested in prospective trials.
The choice of pemetrexed and gemcitabine was purposeful in an effort to avoid agents that patients may have received during initial curative-intent therapy. Interestingly, pemetrexed-gemcitabine yielded an objective RR of 35% and SD in 32%, which would be consistent with platinum-containing regimens in this setting and suggests that this combination may be an option for patients previously treated with platinum, taxanes, or 5-fluorouracil.
Finally, this patient population is prone to toxicity and early death. In our study, there were four deaths reported throughout the course of treatment and none were believed to be directly attributed to study. We feel this rate of morbidity and mortality is justified as the alternative for this patient population is to die of PD. Chemoreirradiation remains a potential treatment choice for patients with locoregionally recurrent SCCHN. While still experimental and highly toxic, it has been investigated widely and multi-institutional studies have been carried out in several countries [7, 8, 10] . The critical decision on whether to undertake this aggressive approach with curative-intent versus offering palliative systemic therapy is a difficult one based on multiple factors. Our findings suggest that response to two cycles of non-platinum-based chemotherapy can be used to prognosticate patients and offer an objective and dynamic metric to assist in managing this devastating presentation. Studies to test this hypothesis further should be undertaken. 
